Clinical Trials
25 trialsNCT06492616 2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT05472792 2026-05-26
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07349069 2026-05-22
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT06195306 2026-05-20
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05512364 2026-05-15
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT05941520 2026-05-13
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-05-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07581834 2026-05-12
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Fujian Cancer Hospital
Phase 2 Recruiting
NCT05774951 2026-05-08
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting
NCT06507618 2026-05-08
POWER II
University of Virginia
Phase 3 Recruiting
NCT05982093 2026-04-24
SOLTI-2104
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT04852887 2026-04-23
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT06348134 2026-02-17
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Phase 2 Recruiting
NCT07019363 2026-01-21
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University
Phase 3 Recruiting
NCT05035836 2025-12-22
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06364267 2025-11-18
BabyTears
Ente Ospedaliero Ospedali Galliera
Phase 2 Recruiting
NCT06361940 2025-10-14
MAPPER
Medical College of Wisconsin
Phase 2 Recruiting
NCT07190443 2025-09-29
AURA
Japanese Foundation for Cancer Research
Phase 3 Recruiting
NCT02476786 2025-07-28
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
Phase 2 Recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT03011684 2025-05-08
TALES
University of California, San Francisco
Phase 3 Recruiting
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
NCT02062489 2022-04-27
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT04666961 2022-04-22
HORNEO01
Institut Cancerologie de l'Ouest
Phase 2 Recruiting